Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

ES Gabitzsch, Y Xu, JP Balint, ZC Hartman… - Cancer Immunology …, 2010 - Springer
Abstract Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it
expresses inserted transgenes robustly and augments the innate immune response …
被引用次数：58 相关文章

Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

ES Gabitzsch, Y Xu, JP Balint Jr… - Cancer …, 2010 - pubmed.ncbi.nlm.nih.gov
Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it expresses
inserted transgenes robustly and augments the innate immune response. Strategies to …

Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.

ES Gabitzsch, Y Xu, JP Balint Jr… - Cancer Immunology …, 2010 - search.ebscohost.com
Abstract Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it
expresses inserted transgenes robustly and augments the innate immune response …

Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

ES Gabitzsch, Y Xu, JP Balint Jr, ZC Hartman… - Cancer Immunology …, 2010 - hero.epa.gov
Abstract Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it
expresses inserted transgenes robustly and augments the innate immune response …
[PDF] google.com

[PDF][PDF] Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

ES Gabitzsch, Y Xu, JP Balint, ZC Hartman… - Cancer Immunology …, 2010 - drive.google.com
Abstract Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it
expresses inserted transgenes robustly and augments the innate immune response …

Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.

ES Gabitzsch, Y Xu, JP Balint Jr… - Cancer Immunology …, 2010 - europepmc.org
Abstract Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it
expresses inserted transgenes robustly and augments the innate immune response …
[HTML] nih.gov

[HTML][HTML] Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

ES Gabitzsch, Y Xu, JP Balint Jr… - Cancer Immunology …, 2010 - ncbi.nlm.nih.gov
Abstract Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it
expresses inserted transgenes robustly and augments the innate immune response …

Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

ES Gabitzsch, Y Xu, JP Balint, ZC Hartman… - Cancer Immunology …, 2010 - infona.pl
Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it expresses
inserted transgenes robustly and augments the innate immune response. Strategies to …

[引用][C] Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

ES Gabitzsch, Y Xu, JP Balint, ZC Hartman… - Cancer Immunology …, 2010 - Springer

[引用][C] Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

ES GABITZSCH, XU YOUNONG, JP BALINT… - Cancer immunology and …, 2010 - Springer